Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps

Hanna K Mandl; Jessa E Miller; Daniel M Beswick

doi:10.1016/j.otc.2023.08.006

Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps

Otolaryngol Clin North Am. 2024 Apr;57(2):225-242. doi: 10.1016/j.otc.2023.08.006. Epub 2023 Sep 9.

Authors

Hanna K Mandl¹, Jessa E Miller², Daniel M Beswick³

Affiliations

¹ University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA.
² Department of Otolaryngology-Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA, USA.
³ Department of Otolaryngology-Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: [email protected].

PMID: 37684154
DOI: 10.1016/j.otc.2023.08.006

Abstract

A substantial portion of asthma and nasal polyps (NPs) share a common pathogenesis, which includes type 2-mediated inflammation. Distinct endotypes and phenotypes characterizing asthma and chronic rhinosinusitis have been identified. With emerging evidence describing pathophysiology, novel targets for biologic monoclonal antibody treatments have been developed. There are currently six biologic therapies approved by the US Food and Drug Administration to treat asthma, including omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab, three of these-omalizumab, mepolizumab, and dupilumab-are also approved for NPs.

Keywords: Asthma; Biologics; Chronic rhinosinusitis; Endotypes; Nasal polyps; Phenotypes; Th2-mediated inflammation.

Publication types

Review

MeSH terms

Asthma* / drug therapy
Biological Therapy
Humans
Nasal Polyps* / drug therapy
Omalizumab / therapeutic use
United States

Substances

Omalizumab

Supplementary concepts

Asthma and Nasal Polyps